title: Psoriasis during natalizumab treatment for multiple sclerosis.
abstract: Beta-interferon therapy is known to trigger psoriasis, but this effect has not been  previously reported for other multiple sclerosis treatments, such as natalizumab. The following is a case report. A 31-year-old woman affected by psoriasis and relapsing-remitting multiple sclerosis suffered a severe worsening of psoriasis symptoms during natalizumab treatment and acquired a drug-resistant course. This case suggests that aggravation of psoriasis might be a rare side effect of natalizumab, and that clinicians should be aware of the possibility  of paradoxical activation of autoimmune diseases during its treatment.
authors.affiliation: Department of Neurology, Hospital General de Tomelloso, Tomelloso, Ciudad Real, Spain. jorge.millan.pascual@gmail.com
authors.forename: Jorge
authors.initials: J
authors.lastname: Millán-Pascual
authors.forename: Laura
authors.initials: L
authors.lastname: Turpín-Fenoll
authors.forename: Pablo
authors.initials: P
authors.lastname: Del Saz-Saucedo
authors.forename: Ignacio
authors.initials: I
authors.lastname: Rueda-Medina
authors.forename: Santiago
authors.initials: S
authors.lastname: Navarro-Muñoz
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab